Granules India share news, announcements and annual reports
NSE: GRANULESBSE: 532482Pharmaceuticals & BiotechnologySmall Cap
Granules India Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2002 on BSE, Jun 2005 on NSE
Last close ₹839.75up ₹2.40 (0.29%)BSE ₹839.55
Share price at the NSE close on 30 Oct 2026. Previous close ₹837.35.
30 Oct: open ₹839.40, high ₹859.70, low ₹837.00
52-week range of traded prices to 30 Oct 2026
₹529.85Low, 25 Nov 2025₹923.65High, 15 Sep 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹22,907 Cr403rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.58
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.21%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,78,58145.0% delivered
Granules India share news and announcements
1,064 announcements, routine notices left out, newest first. Page 22 of 22.
Mar 2007
22 Mar · Meeting
The shareholders of the Company at the Extraordinary General Meeting held on 21st March 2007 had unanimously approved the issue of 22,11,200 equity shares of the Company of the face value of Rs.10/- each fully paid-up on preferential basis to Ridgeback Capital Investment LLC or their affiliates at a price of Rs.105.50/- per share (including premium)12 Mar · Inter-se-transfer
Mr. C. Krishna Prasad, Managing Director and Promoter of the Company holding 34,94,254 (27.79%) had transferred 44,000 (0.35%) shares of the Company, to his son Mr.C.Harsha, Employee and Promoter of the Company6 Mar · Business
Granules India Limited had informed the Exchange regarding Setting up of a Joint Venture in China . The Company has informed the Exchange that the Agreement entered between Granules India Limited and Hubei Biocause Heilen Pharmaceutical Company Limited, China for setting up of a Joint Venture Company in China has been approved by the Government of China. The Joint Venture Company in the name of Hubei Granules Biocause Pharmaceutical Co. Ltd., has been registered and will now become operational. The JV company will manufacture Ibuprofen API presently.5 Mar · Business
Press release dated March 05, 2007 on 'Matchland Pty Ltd, (trading as New Products Development) and Granules India Limited signing an Outsourcing Agreement'. The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Meeting
Notice of Extra Ordinary General Meeting of the members of the Company to be held on 21st March, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements). For more details click here.
Feb 2007
26 Feb · Board meeting
February 25, 2007 that "The Board of Directors of the Company at their meeting held today had considered and approved issue of 22,11,200 equity shares of Rs. 10/- each fully paid-up at Rs. 105.50 per share (including premium) to Ridgeback Capital Investment LLC., or their affiliates on preferential basis, subject to the approval of the shareholders at the Extra Ordinary General Meeting to be held on Wednesday, the 21st day of March, 2007".19 Feb · Disclosure
The Company on 12/2/2007 has received disclosure under regulation 13 (4) of SEBI (Prohibition of Insider Trading) Regulations, 1992 from Mr. N.R.Ganti, Director of the Company, for sale of 20,000 shares (0.16%) out of 21,800 shares (0.17%) held by him19 Feb · Issue of Warrants
February 17, 2007 that "shareholders of the Company at the Extraordinary General Meeting held today have unanimously approved 'issue of warrants convertible into equity shares of the Company to the promoters of the Company'."19 Feb · Board meeting
Inter-alia to consider the "Issue of equity shares to Investor(s) on preferential basis" subject to the approval of the shareholders of the Company.
Jan 2007
31 Jan · Meeting
Notice of Extra Ordinary General Meeting of the members of the Company to be held on 17th February, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements). For more details click here.22 Jan · Board meeting
January 19, 2007 that: "The Board of Directors at their meeting held today considered and approved the following: i) Allotment of 1,94,037 shares to Mr.C.Krishna Prasad, Managing Director and Promoter of the Company against conversion of 1,94,037 warrants out of 13,55,000 warrants issued on preferential basis; ii) Issue of 16,00,000 warrants convertible into 16,00,000 equity shares of Rs.10/- each of the Company, on preferential basis to the promoters of the Company, subject to the approval of shareholders at the General Meeting".19 Jan · Business
Press release dated January 19, 2007, titled "Granules India posts 37% growth in Net Profit in Q2 FY07". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Business
Press release dated January 17, 2007 which is as follows: "Granules India is pleased to announce the signing of a Master Service Agreement with GlaxoSmithKline Consumer Healthcare R&D (GSK CH R&D). This agreement is the first step in this new relationship that will involve Granules undertaking product development projects".9 Jan · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the second quarter ended 31st December, 2006.